Abstract
Currently, only patients with metastatic triple-negative breast cancer whose tumors are PD-L1 positive are eligible for receiving immunotherapy. Other studies have explored new combinations with PD-1/PD-L1 inhibitors in different disease settings and populations. Data from neoadjuvant trials testing the addition of PD-1/PD-L1 inhibitors to standard treatment are promising and have led to increases in pathologic complete response rates; however, data on survival outcomes are still immature. There is still much work needed to optimize benefits of immunotherapy in breast cancer and correlative studies in patients treated with immunotherapy are urgently needed to inform the best strategies for further development.
Keywords:
Breast cancer; Immune checkpoint inhibitors; Immunotherapy; PD-1 inhibitors; PD-L1 inhibitors.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
B7-H1 Antigen / antagonists & inhibitors*
-
Biomarkers, Tumor
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / etiology
-
Breast Neoplasms / mortality
-
Clinical Decision-Making
-
Clinical Studies as Topic
-
Combined Modality Therapy
-
Disease Management
-
Disease Susceptibility
-
Female
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immune Checkpoint Inhibitors / adverse effects
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Immune Checkpoint Proteins
-
Molecular Targeted Therapy* / adverse effects
-
Molecular Targeted Therapy* / methods
-
Neoplasm Staging
-
Prognosis
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Treatment Outcome
Substances
-
B7-H1 Antigen
-
Biomarkers, Tumor
-
CD274 protein, human
-
Immune Checkpoint Inhibitors
-
Immune Checkpoint Proteins
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor